Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD.

Abstract

The Nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) has been applied as a method for evaluating treatment response, and a ≥2-point improvement in NAS has been commonly used as an accepted end point in phase 2b clinical trials in nonalcoholic steatohepatitis.1,2 Although liver fibrosis is the strongest histologic predictor of liver-related outcome and all-cause mortality in NAFLD,3,4 the association between change in NAS and change in fibrosis stage has not been fully verified. Therefore, we aimed to examine the association between change in NAS and change in fibrosis stage in well-characterized patients with NAFLD who had a paired liver biopsy assessment.

• Authors: Nobuharu Tamaki, Nagambika Munaganuru, Jinho Jung, Aed Qas Yonan, Richele Bettencourt, Veeral Ajmera, Mark A Valasek, Cynthia Behling, Rohit Loomba
• Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (Clin Gastroenterol Hepatol) Vol. 19 Issue 12 Pg. 2673-2674.e3 (12 2021) ISSN: 1542-7714 [Electronic] United States
• PMID: 33157318 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Topics

• Biopsy
• Fibrosis
• Humans
• Liver (pathology)
• Liver Cirrhosis (diagnosis, pathology)
• Non-alcoholic Fatty Liver Disease (complications, pathology)
• Severity of Illness Index